| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement Activation | 45 | 2021 | 145 | 9.480 |
Why?
|
| Complement System Proteins | 33 | 2023 | 135 | 8.480 |
Why?
|
| Complement Inactivating Agents | 22 | 2021 | 56 | 6.800 |
Why?
|
| Recombinant Fusion Proteins | 39 | 2022 | 376 | 5.240 |
Why?
|
| Reperfusion Injury | 17 | 2021 | 320 | 5.000 |
Why?
|
| Complement Pathway, Alternative | 21 | 2021 | 69 | 4.640 |
Why?
|
| Complement C3 | 31 | 2022 | 101 | 4.490 |
Why?
|
| Receptors, Complement 3d | 19 | 2017 | 45 | 3.300 |
Why?
|
| Brain Injuries, Traumatic | 5 | 2021 | 105 | 3.200 |
Why?
|
| Mice | 93 | 2022 | 8474 | 2.880 |
Why?
|
| Mice, Inbred C57BL | 55 | 2021 | 2791 | 2.820 |
Why?
|
| Receptors, Complement | 18 | 2019 | 58 | 2.630 |
Why?
|
| Receptors, Complement 3b | 14 | 2021 | 35 | 2.440 |
Why?
|
| Immunoglobulin M | 10 | 2021 | 172 | 2.440 |
Why?
|
| Animals | 113 | 2022 | 20881 | 2.390 |
Why?
|
| Complement Inactivator Proteins | 11 | 2015 | 20 | 2.150 |
Why?
|
| Stroke | 11 | 2021 | 2163 | 2.030 |
Why?
|
| Antibodies, Monoclonal | 14 | 2021 | 511 | 1.990 |
Why?
|
| Heart Transplantation | 5 | 2021 | 328 | 1.930 |
Why?
|
| CD59 Antigens | 15 | 2017 | 30 | 1.890 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2021 | 84 | 1.870 |
Why?
|
| Disease Models, Animal | 32 | 2021 | 2550 | 1.790 |
Why?
|
| Cognitive Dysfunction | 3 | 2021 | 176 | 1.770 |
Why?
|
| Single-Chain Antibodies | 4 | 2021 | 15 | 1.670 |
Why?
|
| Vascularized Composite Allotransplantation | 3 | 2021 | 17 | 1.550 |
Why?
|
| Liver Regeneration | 4 | 2017 | 38 | 1.510 |
Why?
|
| Mice, Knockout | 30 | 2022 | 1692 | 1.470 |
Why?
|
| Hindlimb | 2 | 2021 | 38 | 1.360 |
Why?
|
| Synapses | 3 | 2021 | 222 | 1.350 |
Why?
|
| Brain Ischemia | 6 | 2018 | 665 | 1.270 |
Why?
|
| Inflammation | 10 | 2022 | 1030 | 1.250 |
Why?
|
| Colitis | 3 | 2015 | 156 | 1.250 |
Why?
|
| Microglia | 5 | 2021 | 143 | 1.250 |
Why?
|
| Complement Factor H | 8 | 2015 | 21 | 1.200 |
Why?
|
| Inflammation Mediators | 3 | 2021 | 244 | 1.140 |
Why?
|
| Liver | 7 | 2022 | 1118 | 1.140 |
Why?
|
| Regeneration | 3 | 2019 | 105 | 1.130 |
Why?
|
| Complement Membrane Attack Complex | 9 | 2018 | 20 | 1.120 |
Why?
|
| Recovery of Function | 10 | 2021 | 506 | 1.100 |
Why?
|
| Mice, Inbred BALB C | 19 | 2021 | 532 | 1.090 |
Why?
|
| P-Selectin | 2 | 2021 | 16 | 1.080 |
Why?
|
| Complement C2 | 2 | 2021 | 9 | 0.980 |
Why?
|
| Spinal Cord Injuries | 5 | 2018 | 551 | 0.960 |
Why?
|
| Choroidal Neovascularization | 7 | 2021 | 35 | 0.960 |
Why?
|
| Lymphoma | 5 | 2015 | 116 | 0.940 |
Why?
|
| Autoantibodies | 4 | 2017 | 434 | 0.900 |
Why?
|
| Complement C3d | 3 | 2018 | 10 | 0.900 |
Why?
|
| Molecular Targeted Therapy | 6 | 2021 | 170 | 0.890 |
Why?
|
| Complement Pathway, Classical | 4 | 2020 | 22 | 0.890 |
Why?
|
| Central Nervous System | 2 | 2021 | 107 | 0.880 |
Why?
|
| Epitopes | 3 | 2021 | 146 | 0.870 |
Why?
|
| Neuroprotective Agents | 3 | 2020 | 317 | 0.850 |
Why?
|
| Intestines | 4 | 2015 | 114 | 0.830 |
Why?
|
| Brain Death | 3 | 2021 | 34 | 0.810 |
Why?
|
| Cell Adhesion | 3 | 2021 | 324 | 0.800 |
Why?
|
| Hydrocephalus | 1 | 2022 | 40 | 0.800 |
Why?
|
| Brain Injury, Chronic | 1 | 2021 | 4 | 0.790 |
Why?
|
| Organ Specificity | 4 | 2016 | 167 | 0.760 |
Why?
|
| Adaptive Immunity | 3 | 2023 | 37 | 0.760 |
Why?
|
| Macular Degeneration | 6 | 2016 | 75 | 0.740 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 198 | 0.720 |
Why?
|
| Central Nervous System Diseases | 1 | 2020 | 40 | 0.720 |
Why?
|
| Retinal Diseases | 1 | 2020 | 40 | 0.720 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 234 | 0.710 |
Why?
|
| Stroke Rehabilitation | 2 | 2021 | 335 | 0.710 |
Why?
|
| Male | 36 | 2021 | 37321 | 0.690 |
Why?
|
| Immunity, Innate | 5 | 2021 | 156 | 0.690 |
Why?
|
| Tissue Donors | 2 | 2013 | 195 | 0.680 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 142 | 0.670 |
Why?
|
| Lupus Nephritis | 3 | 2011 | 193 | 0.660 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2020 | 296 | 0.660 |
Why?
|
| Fibrinolytic Agents | 2 | 2021 | 377 | 0.650 |
Why?
|
| Graft Survival | 2 | 2021 | 465 | 0.640 |
Why?
|
| Receptor, Anaphylatoxin C5a | 6 | 2019 | 20 | 0.630 |
Why?
|
| Physical Conditioning, Animal | 1 | 2018 | 34 | 0.620 |
Why?
|
| Humans | 62 | 2022 | 68618 | 0.610 |
Why?
|
| Immunosuppressive Agents | 4 | 2017 | 514 | 0.610 |
Why?
|
| Phagocytosis | 4 | 2021 | 65 | 0.600 |
Why?
|
| Arthritis, Experimental | 4 | 2020 | 38 | 0.600 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2008 | 138 | 0.590 |
Why?
|
| Immunoglobulin G | 7 | 2012 | 481 | 0.580 |
Why?
|
| Composite Tissue Allografts | 1 | 2017 | 8 | 0.580 |
Why?
|
| Cyclosporine | 1 | 2017 | 121 | 0.550 |
Why?
|
| Intestinal Mucosa | 3 | 2014 | 219 | 0.550 |
Why?
|
| Gene Targeting | 1 | 2015 | 58 | 0.520 |
Why?
|
| CD55 Antigens | 4 | 2009 | 13 | 0.520 |
Why?
|
| Neurons | 2 | 2018 | 881 | 0.520 |
Why?
|
| Thromboembolism | 1 | 2016 | 91 | 0.510 |
Why?
|
| T-Lymphocytes | 5 | 2023 | 597 | 0.510 |
Why?
|
| Disease Susceptibility | 4 | 2020 | 179 | 0.510 |
Why?
|
| Self Tolerance | 1 | 2015 | 8 | 0.500 |
Why?
|
| Antibodies, Bispecific | 1 | 2015 | 12 | 0.500 |
Why?
|
| Myocardial Reperfusion | 1 | 2015 | 32 | 0.500 |
Why?
|
| Immunomodulation | 1 | 2014 | 35 | 0.470 |
Why?
|
| Mucin-1 | 3 | 2008 | 35 | 0.470 |
Why?
|
| Macrophages | 6 | 2022 | 647 | 0.470 |
Why?
|
| Retina | 5 | 2020 | 252 | 0.460 |
Why?
|
| Antibodies | 4 | 2013 | 241 | 0.460 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2019 | 163 | 0.450 |
Why?
|
| Rats | 9 | 2022 | 5300 | 0.450 |
Why?
|
| Retinal Pigment Epithelium | 6 | 2021 | 145 | 0.450 |
Why?
|
| Colon | 1 | 2014 | 168 | 0.450 |
Why?
|
| Liver Transplantation | 5 | 2017 | 400 | 0.450 |
Why?
|
| Brain | 2 | 2021 | 2176 | 0.440 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2011 | 756 | 0.430 |
Why?
|
| Intestinal Diseases | 2 | 2011 | 25 | 0.420 |
Why?
|
| Neutrophils | 5 | 2015 | 204 | 0.420 |
Why?
|
| Signal Transduction | 11 | 2021 | 2689 | 0.410 |
Why?
|
| Liver Neoplasms | 4 | 2019 | 334 | 0.410 |
Why?
|
| Immunotherapy | 3 | 2012 | 215 | 0.400 |
Why?
|
| Autoimmunity | 2 | 2016 | 118 | 0.390 |
Why?
|
| Prostatic Neoplasms | 3 | 2007 | 778 | 0.380 |
Why?
|
| Complement C9 | 3 | 2011 | 5 | 0.380 |
Why?
|
| Female | 27 | 2020 | 38074 | 0.380 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2020 | 105 | 0.380 |
Why?
|
| Myelitis | 1 | 2010 | 9 | 0.370 |
Why?
|
| Kidney Diseases | 2 | 2011 | 307 | 0.370 |
Why?
|
| Acepromazine | 1 | 2010 | 3 | 0.350 |
Why?
|
| Xylazine | 1 | 2010 | 5 | 0.350 |
Why?
|
| Complement C3a | 1 | 2009 | 3 | 0.350 |
Why?
|
| Dextran Sulfate | 3 | 2015 | 88 | 0.340 |
Why?
|
| Immunohistochemistry | 8 | 2016 | 1174 | 0.330 |
Why?
|
| Ketamine | 1 | 2010 | 57 | 0.330 |
Why?
|
| Fatty Liver | 1 | 2009 | 97 | 0.330 |
Why?
|
| Neutrophil Infiltration | 5 | 2015 | 35 | 0.320 |
Why?
|
| Complement C1q | 4 | 2012 | 18 | 0.300 |
Why?
|
| Receptors, Fc | 1 | 2007 | 19 | 0.300 |
Why?
|
| Cell Line, Tumor | 10 | 2019 | 1851 | 0.300 |
Why?
|
| Nerve Degeneration | 2 | 2018 | 134 | 0.300 |
Why?
|
| Hepatectomy | 3 | 2014 | 58 | 0.300 |
Why?
|
| Drug Delivery Systems | 4 | 2021 | 236 | 0.300 |
Why?
|
| Dendritic Cells | 3 | 2020 | 201 | 0.290 |
Why?
|
| Graft vs Host Disease | 2 | 2020 | 163 | 0.290 |
Why?
|
| Lung Diseases | 1 | 2008 | 175 | 0.280 |
Why?
|
| Homeodomain Proteins | 3 | 2017 | 157 | 0.280 |
Why?
|
| CHO Cells | 6 | 2011 | 161 | 0.270 |
Why?
|
| Cricetinae | 6 | 2011 | 262 | 0.270 |
Why?
|
| Time Factors | 7 | 2018 | 4655 | 0.270 |
Why?
|
| CD2 Antigens | 1 | 2005 | 8 | 0.270 |
Why?
|
| Chemotaxis, Leukocyte | 3 | 2017 | 48 | 0.260 |
Why?
|
| Protein Interaction Maps | 2 | 2015 | 30 | 0.260 |
Why?
|
| Apoptosis | 6 | 2020 | 1641 | 0.250 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2005 | 81 | 0.250 |
Why?
|
| Communicable Diseases | 1 | 2005 | 50 | 0.250 |
Why?
|
| Nephrotic Syndrome | 1 | 2005 | 61 | 0.240 |
Why?
|
| Sphingomyelin Phosphodiesterase | 2 | 2019 | 183 | 0.240 |
Why?
|
| Mucins | 1 | 2004 | 22 | 0.230 |
Why?
|
| Lasers | 2 | 2017 | 61 | 0.230 |
Why?
|
| Cytokines | 3 | 2014 | 866 | 0.230 |
Why?
|
| Models, Animal | 2 | 2017 | 252 | 0.230 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2004 | 44 | 0.230 |
Why?
|
| Graft Rejection | 3 | 2013 | 458 | 0.230 |
Why?
|
| Ischemia | 2 | 2018 | 229 | 0.230 |
Why?
|
| Mitochondria | 2 | 2019 | 643 | 0.230 |
Why?
|
| Survival Rate | 4 | 2013 | 1056 | 0.230 |
Why?
|
| Kidney | 4 | 2011 | 945 | 0.230 |
Why?
|
| Locomotion | 2 | 2017 | 135 | 0.220 |
Why?
|
| Complement C4 | 2 | 2021 | 15 | 0.220 |
Why?
|
| Homeostasis | 2 | 2016 | 291 | 0.220 |
Why?
|
| Flow Cytometry | 5 | 2014 | 489 | 0.220 |
Why?
|
| Protein Binding | 5 | 2017 | 1027 | 0.220 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 99 | 0.220 |
Why?
|
| Dexamethasone | 1 | 2004 | 150 | 0.220 |
Why?
|
| Tumor Escape | 2 | 2016 | 37 | 0.220 |
Why?
|
| Pneumonia | 2 | 2018 | 110 | 0.220 |
Why?
|
| Disease Progression | 3 | 2022 | 1038 | 0.210 |
Why?
|
| Liver Failure, Acute | 2 | 2014 | 49 | 0.210 |
Why?
|
| Neoplasms | 2 | 2012 | 1667 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 710 | 0.210 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2006 | 114 | 0.210 |
Why?
|
| Lung | 3 | 2013 | 849 | 0.210 |
Why?
|
| Inflammasomes | 1 | 2022 | 39 | 0.210 |
Why?
|
| Glucocorticoids | 1 | 2004 | 222 | 0.200 |
Why?
|
| Acute Lung Injury | 2 | 2013 | 35 | 0.200 |
Why?
|
| Neuroimmunomodulation | 1 | 2021 | 16 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2011 | 507 | 0.200 |
Why?
|
| Trophoblasts | 2 | 2018 | 29 | 0.190 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 168 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 87 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 29 | 0.190 |
Why?
|
| Cholestasis | 1 | 2022 | 90 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2015 | 626 | 0.190 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 475 | 0.190 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 3 | 2011 | 17 | 0.190 |
Why?
|
| Transplants | 1 | 2021 | 28 | 0.190 |
Why?
|
| Animals, Newborn | 1 | 2022 | 396 | 0.190 |
Why?
|
| Cell Line | 8 | 2021 | 1752 | 0.190 |
Why?
|
| Synoviocytes | 1 | 2020 | 2 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2022 | 2083 | 0.190 |
Why?
|
| Maze Learning | 1 | 2021 | 138 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2015 | 219 | 0.190 |
Why?
|
| Lung Injury | 1 | 2021 | 38 | 0.190 |
Why?
|
| Insulin Resistance | 1 | 2022 | 241 | 0.180 |
Why?
|
| Joints | 1 | 2020 | 30 | 0.180 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 59 | 0.180 |
Why?
|
| Lung Neoplasms | 2 | 2008 | 1173 | 0.180 |
Why?
|
| Blotting, Western | 7 | 2021 | 954 | 0.180 |
Why?
|
| Retinal Degeneration | 1 | 2021 | 75 | 0.180 |
Why?
|
| Reperfusion | 1 | 2020 | 78 | 0.180 |
Why?
|
| Tissue Distribution | 2 | 2014 | 282 | 0.170 |
Why?
|
| Lung Transplantation | 1 | 2021 | 88 | 0.170 |
Why?
|
| Opsonin Proteins | 2 | 2018 | 4 | 0.170 |
Why?
|
| Transcriptome | 1 | 2021 | 164 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 1536 | 0.170 |
Why?
|
| Complement C8 | 2 | 2011 | 4 | 0.170 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2019 | 3 | 0.170 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2019 | 5 | 0.170 |
Why?
|
| Mice, Inbred MRL lpr | 2 | 2011 | 118 | 0.170 |
Why?
|
| Transfection | 6 | 2021 | 782 | 0.170 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2019 | 4 | 0.170 |
Why?
|
| Binding Sites | 4 | 2011 | 631 | 0.170 |
Why?
|
| Neoplasm Metastasis | 2 | 2012 | 306 | 0.170 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2018 | 5 | 0.160 |
Why?
|
| Melanoma | 1 | 2022 | 335 | 0.160 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 498 | 0.160 |
Why?
|
| Spleen | 2 | 2017 | 301 | 0.160 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 61 | 0.160 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2018 | 57 | 0.160 |
Why?
|
| Organelle Biogenesis | 1 | 2018 | 34 | 0.160 |
Why?
|
| Molecular Chaperones | 2 | 2013 | 81 | 0.160 |
Why?
|
| Formoterol Fumarate | 1 | 2018 | 25 | 0.160 |
Why?
|
| Demyelinating Diseases | 2 | 2010 | 57 | 0.160 |
Why?
|
| Antigen-Antibody Complex | 2 | 2011 | 175 | 0.160 |
Why?
|
| Gene Expression | 3 | 2012 | 770 | 0.160 |
Why?
|
| Rhinosporidiosis | 1 | 2018 | 7 | 0.160 |
Why?
|
| B-Lymphocytes | 2 | 2017 | 329 | 0.160 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2018 | 27 | 0.160 |
Why?
|
| Transplantation, Homologous | 3 | 2020 | 242 | 0.160 |
Why?
|
| Mice, Inbred NZB | 2 | 2011 | 37 | 0.160 |
Why?
|
| Biomarkers | 2 | 2021 | 1593 | 0.160 |
Why?
|
| Fetus | 1 | 2018 | 157 | 0.150 |
Why?
|
| Glaucoma | 1 | 2018 | 50 | 0.150 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 233 | 0.150 |
Why?
|
| Neuroprotection | 1 | 2018 | 28 | 0.150 |
Why?
|
| Dendrites | 1 | 2018 | 44 | 0.150 |
Why?
|
| Myocardium | 2 | 2015 | 1204 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2018 | 114 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 848 | 0.150 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 1033 | 0.150 |
Why?
|
| Thrombectomy | 1 | 2020 | 238 | 0.150 |
Why?
|
| Up-Regulation | 3 | 2016 | 682 | 0.150 |
Why?
|
| Recombinant Proteins | 4 | 2007 | 742 | 0.140 |
Why?
|
| Pyramidal Tracts | 1 | 2017 | 45 | 0.140 |
Why?
|
| Mice, Inbred DBA | 3 | 2020 | 120 | 0.140 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2016 | 6 | 0.140 |
Why?
|
| Protein Structure, Tertiary | 2 | 2008 | 322 | 0.140 |
Why?
|
| Models, Immunological | 2 | 2015 | 25 | 0.140 |
Why?
|
| Chronic Disease | 3 | 2018 | 1330 | 0.140 |
Why?
|
| RNA, Messenger | 3 | 2011 | 1664 | 0.140 |
Why?
|
| Neoplasms, Experimental | 3 | 2006 | 118 | 0.140 |
Why?
|
| Electroretinography | 3 | 2016 | 122 | 0.140 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2013 | 4 | 0.140 |
Why?
|
| Functional Laterality | 1 | 2017 | 240 | 0.130 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2015 | 2 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2020 | 7029 | 0.130 |
Why?
|
| Complement Factor B | 2 | 2012 | 19 | 0.130 |
Why?
|
| Phenotype | 2 | 2017 | 947 | 0.130 |
Why?
|
| Gene Expression Regulation | 3 | 2018 | 1293 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2016 | 124 | 0.130 |
Why?
|
| Smoke | 1 | 2016 | 46 | 0.130 |
Why?
|
| Epithelial Cells | 3 | 2018 | 431 | 0.130 |
Why?
|
| Placental Insufficiency | 1 | 2015 | 1 | 0.130 |
Why?
|
| Placentation | 1 | 2015 | 6 | 0.130 |
Why?
|
| Thiolester Hydrolases | 1 | 2015 | 2 | 0.130 |
Why?
|
| Brain Injuries | 1 | 2019 | 268 | 0.130 |
Why?
|
| Brain Infarction | 1 | 2016 | 54 | 0.130 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 167 | 0.130 |
Why?
|
| Astrocytes | 1 | 2018 | 270 | 0.130 |
Why?
|
| Abortion, Spontaneous | 1 | 2015 | 17 | 0.130 |
Why?
|
| Mannose-Binding Lectin | 1 | 2015 | 3 | 0.130 |
Why?
|
| Annexin A4 | 1 | 2015 | 2 | 0.130 |
Why?
|
| Genes, Synthetic | 1 | 2015 | 5 | 0.130 |
Why?
|
| Immune System Diseases | 1 | 2015 | 12 | 0.130 |
Why?
|
| Immunity, Mucosal | 1 | 2015 | 19 | 0.130 |
Why?
|
| Transplantation Tolerance | 1 | 2015 | 13 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 2 | 2017 | 89 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 756 | 0.120 |
Why?
|
| Genotype | 1 | 2017 | 786 | 0.120 |
Why?
|
| Phospholipids | 1 | 2015 | 108 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 415 | 0.120 |
Why?
|
| Subcutaneous Tissue | 1 | 2014 | 6 | 0.120 |
Why?
|
| Triterpenes | 1 | 2015 | 40 | 0.120 |
Why?
|
| Interleukin-1alpha | 1 | 2014 | 5 | 0.120 |
Why?
|
| Genetic Therapy | 3 | 2018 | 291 | 0.120 |
Why?
|
| Adenoviridae Infections | 1 | 2014 | 6 | 0.120 |
Why?
|
| Placenta | 2 | 2015 | 101 | 0.120 |
Why?
|
| Drug Design | 2 | 2013 | 107 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 384 | 0.120 |
Why?
|
| Cell Movement | 3 | 2016 | 630 | 0.110 |
Why?
|
| Prognosis | 4 | 2021 | 2093 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2017 | 384 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2014 | 59 | 0.110 |
Why?
|
| Antigens, Surface | 2 | 2005 | 71 | 0.110 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2013 | 1 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2008 | 852 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2016 | 617 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2021 | 1615 | 0.110 |
Why?
|
| Melanoma, Experimental | 2 | 2012 | 95 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 290 | 0.110 |
Why?
|
| Airway Remodeling | 1 | 2013 | 7 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2014 | 411 | 0.110 |
Why?
|
| Mitochondria, Liver | 1 | 2014 | 148 | 0.110 |
Why?
|
| Complement C5a | 1 | 2013 | 15 | 0.110 |
Why?
|
| Mice, Nude | 2 | 2019 | 294 | 0.110 |
Why?
|
| Receptors, Opioid, delta | 1 | 2013 | 37 | 0.110 |
Why?
|
| Enterovirus A, Human | 1 | 2012 | 3 | 0.110 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 314 | 0.110 |
Why?
|
| Neurogenic Inflammation | 1 | 2012 | 4 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2015 | 447 | 0.110 |
Why?
|
| Complement C6 | 1 | 2012 | 3 | 0.110 |
Why?
|
| Cricetulus | 3 | 2011 | 98 | 0.110 |
Why?
|
| Complement Pathway, Mannose-Binding Lectin | 1 | 2012 | 4 | 0.110 |
Why?
|
| Mice, Mutant Strains | 2 | 2010 | 166 | 0.110 |
Why?
|
| Kinetics | 1 | 2014 | 1047 | 0.110 |
Why?
|
| DNA | 2 | 2016 | 597 | 0.110 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 63 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 57 | 0.110 |
Why?
|
| Complement C3-C5 Convertases | 1 | 2012 | 1 | 0.110 |
Why?
|
| Thrombin | 1 | 2013 | 117 | 0.100 |
Why?
|
| Malaria, Cerebral | 1 | 2012 | 3 | 0.100 |
Why?
|
| ELAV Proteins | 1 | 2012 | 17 | 0.100 |
Why?
|
| 2-Acetylaminofluorene | 1 | 2012 | 3 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 248 | 0.100 |
Why?
|
| Cell Division | 2 | 2004 | 541 | 0.100 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 148 | 0.100 |
Why?
|
| Caspases | 1 | 2012 | 194 | 0.100 |
Why?
|
| Immunoconjugates | 1 | 2012 | 26 | 0.100 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2011 | 10 | 0.100 |
Why?
|
| Galactosamine | 1 | 2011 | 11 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 235 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2014 | 204 | 0.100 |
Why?
|
| Allergens | 1 | 2011 | 54 | 0.100 |
Why?
|
| Trachea | 1 | 2011 | 48 | 0.100 |
Why?
|
| Macrophage-1 Antigen | 2 | 2009 | 10 | 0.100 |
Why?
|
| Bacteriocins | 1 | 2011 | 4 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.100 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2012 | 133 | 0.100 |
Why?
|
| Paraquat | 1 | 2011 | 8 | 0.100 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2011 | 43 | 0.100 |
Why?
|
| Biopsy | 1 | 2013 | 540 | 0.090 |
Why?
|
| Shock, Hemorrhagic | 1 | 2011 | 33 | 0.090 |
Why?
|
| Albuminuria | 1 | 2011 | 171 | 0.090 |
Why?
|
| Kidney Tubules | 1 | 2011 | 80 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2010 | 94 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 4848 | 0.090 |
Why?
|
| Hepatocytes | 1 | 2012 | 205 | 0.090 |
Why?
|
| Interleukin-12 | 1 | 2011 | 75 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 370 | 0.090 |
Why?
|
| Middle Aged | 3 | 2020 | 21147 | 0.090 |
Why?
|
| Stem Cells | 1 | 2012 | 248 | 0.090 |
Why?
|
| Orthomyxoviridae | 1 | 2010 | 6 | 0.090 |
Why?
|
| Anesthetics, Combined | 1 | 2010 | 2 | 0.090 |
Why?
|
| Anesthesia Recovery Period | 1 | 2010 | 11 | 0.090 |
Why?
|
| Isoflurane | 1 | 2010 | 16 | 0.090 |
Why?
|
| Anesthetics, Inhalation | 1 | 2010 | 21 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 226 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2010 | 765 | 0.090 |
Why?
|
| Collagen Type II | 1 | 2009 | 13 | 0.090 |
Why?
|
| Rats, Inbred Lew | 1 | 2010 | 150 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 114 | 0.090 |
Why?
|
| Molecular Sequence Data | 3 | 2007 | 1447 | 0.090 |
Why?
|
| Ischemic Preconditioning | 1 | 2009 | 31 | 0.090 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 455 | 0.080 |
Why?
|
| Sheep | 2 | 2015 | 128 | 0.080 |
Why?
|
| Erythrocytes | 2 | 2015 | 137 | 0.080 |
Why?
|
| Random Allocation | 1 | 2010 | 442 | 0.080 |
Why?
|
| Myocarditis | 1 | 2009 | 49 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2009 | 103 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2010 | 79 | 0.080 |
Why?
|
| Protein Engineering | 2 | 2008 | 35 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 86 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2673 | 0.080 |
Why?
|
| Choroid | 1 | 2009 | 22 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2009 | 95 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 137 | 0.080 |
Why?
|
| Cryptococcus neoformans | 1 | 2009 | 24 | 0.080 |
Why?
|
| Fungal Proteins | 1 | 2009 | 37 | 0.080 |
Why?
|
| Membrane Cofactor Protein | 1 | 2008 | 7 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2010 | 714 | 0.080 |
Why?
|
| HIV-1 | 1 | 2010 | 177 | 0.080 |
Why?
|
| Dimerization | 1 | 2008 | 99 | 0.080 |
Why?
|
| Pre-Eclampsia | 1 | 2010 | 202 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 199 | 0.080 |
Why?
|
| Phospholipase D | 1 | 2008 | 13 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 334 | 0.080 |
Why?
|
| Anesthesia | 1 | 2010 | 120 | 0.080 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2008 | 40 | 0.080 |
Why?
|
| Heart | 1 | 2013 | 850 | 0.080 |
Why?
|
| Complement C3b | 2 | 2004 | 3 | 0.080 |
Why?
|
| Immunoprecipitation | 3 | 2016 | 132 | 0.080 |
Why?
|
| Enzyme Activation | 3 | 2019 | 791 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2009 | 330 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2007 | 546 | 0.070 |
Why?
|
| Heterografts | 2 | 2019 | 70 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 369 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2004 | 66 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2007 | 132 | 0.070 |
Why?
|
| Ceramides | 2 | 2012 | 578 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 245 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 420 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 434 | 0.070 |
Why?
|
| Peptide Library | 1 | 2006 | 16 | 0.070 |
Why?
|
| Hep G2 Cells | 2 | 2019 | 68 | 0.070 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 64 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2008 | 186 | 0.070 |
Why?
|
| Proteome | 2 | 2018 | 87 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 159 | 0.070 |
Why?
|
| Glycosylation | 1 | 2006 | 185 | 0.070 |
Why?
|
| Necrosis | 1 | 2006 | 239 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2009 | 597 | 0.060 |
Why?
|
| Alanine | 1 | 2005 | 38 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2006 | 312 | 0.060 |
Why?
|
| Nephritis, Interstitial | 1 | 2005 | 14 | 0.060 |
Why?
|
| Pregnancy | 3 | 2018 | 2334 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2005 | 97 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 204 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 1 | 2006 | 296 | 0.060 |
Why?
|
| Computational Biology | 1 | 2006 | 190 | 0.060 |
Why?
|
| Receptors, IgG | 1 | 2005 | 94 | 0.060 |
Why?
|
| Neoplasm Proteins | 2 | 2004 | 307 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 492 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2004 | 57 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 223 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2004 | 67 | 0.060 |
Why?
|
| Collagen | 1 | 2007 | 636 | 0.060 |
Why?
|
| Clusterin | 1 | 2004 | 13 | 0.060 |
Why?
|
| Aged | 1 | 2020 | 14862 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2005 | 155 | 0.060 |
Why?
|
| Protein Conformation | 1 | 2005 | 362 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2004 | 61 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2005 | 346 | 0.060 |
Why?
|
| beta-Glucans | 1 | 2004 | 18 | 0.060 |
Why?
|
| Software | 1 | 2006 | 418 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 209 | 0.060 |
Why?
|
| Cell Membrane | 2 | 2004 | 525 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1753 | 0.060 |
Why?
|
| U937 Cells | 1 | 2003 | 61 | 0.060 |
Why?
|
| Peptides | 1 | 2006 | 455 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 282 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 304 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2004 | 238 | 0.050 |
Why?
|
| Microcirculation | 2 | 2013 | 77 | 0.050 |
Why?
|
| HIV Infections | 1 | 2010 | 791 | 0.050 |
Why?
|
| Ligands | 1 | 2003 | 317 | 0.050 |
Why?
|
| Cell Hypoxia | 2 | 2012 | 92 | 0.050 |
Why?
|
| Young Adult | 1 | 2013 | 5717 | 0.050 |
Why?
|
| Cattle | 2 | 2015 | 475 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2022 | 186 | 0.050 |
Why?
|
| Oxidative Stress | 3 | 2010 | 718 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 35 | 0.050 |
Why?
|
| Thymocytes | 1 | 2020 | 11 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 88 | 0.050 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 45 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 561 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2013 | 7277 | 0.050 |
Why?
|
| Biological Products | 2 | 2012 | 78 | 0.040 |
Why?
|
| Adolescent | 1 | 2013 | 8912 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 2 | 2011 | 164 | 0.040 |
Why?
|
| Adenoviridae | 2 | 2014 | 295 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2011 | 304 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2020 | 110 | 0.040 |
Why?
|
| Leukemia | 1 | 2020 | 117 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 126 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 301 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2019 | 17 | 0.040 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 22 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2018 | 16 | 0.040 |
Why?
|
| Dependovirus | 1 | 2018 | 34 | 0.040 |
Why?
|
| Aspergillus fumigatus | 1 | 2018 | 27 | 0.040 |
Why?
|
| Adult | 2 | 2015 | 21403 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2018 | 101 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 84 | 0.040 |
Why?
|
| Intraocular Pressure | 1 | 2018 | 143 | 0.040 |
Why?
|
| Retinal Ganglion Cells | 1 | 2018 | 72 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 68 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 1997 | 35 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1997 | 62 | 0.040 |
Why?
|
| Multigene Family | 1 | 1997 | 93 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 199 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 397 | 0.040 |
Why?
|
| Autophagy | 1 | 2018 | 208 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 53 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1174 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 138 | 0.030 |
Why?
|
| Ceruloplasmin | 1 | 2015 | 8 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2015 | 11 | 0.030 |
Why?
|
| Copper-transporting ATPases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Nasal Polyps | 1 | 2018 | 184 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2016 | 351 | 0.030 |
Why?
|
| Data Curation | 1 | 2015 | 2 | 0.030 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 2 | 2006 | 11 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 14 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2015 | 83 | 0.030 |
Why?
|
| Mice, Inbred CBA | 2 | 2010 | 107 | 0.030 |
Why?
|
| Fetal Death | 1 | 2015 | 49 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2015 | 24 | 0.030 |
Why?
|
| Immunoglobulin D | 1 | 2015 | 14 | 0.030 |
Why?
|
| Antigens, CD19 | 1 | 2015 | 17 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2015 | 98 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2015 | 56 | 0.030 |
Why?
|
| Antigens | 1 | 2015 | 90 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2016 | 236 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 219 | 0.030 |
Why?
|
| Cognition | 1 | 2019 | 513 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 42 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 201 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1034 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 349 | 0.030 |
Why?
|
| Estrogens | 1 | 2015 | 173 | 0.030 |
Why?
|
| Copper | 1 | 2015 | 149 | 0.030 |
Why?
|
| Cell Death | 1 | 2015 | 329 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 536 | 0.030 |
Why?
|
| Elapid Venoms | 1 | 2013 | 5 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 652 | 0.030 |
Why?
|
| Chemokines | 1 | 2014 | 119 | 0.030 |
Why?
|
| Bromodeoxyuridine | 1 | 2013 | 37 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2013 | 29 | 0.030 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2013 | 15 | 0.030 |
Why?
|
| Mice, Inbred ICR | 1 | 2012 | 44 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 127 | 0.030 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 46 | 0.030 |
Why?
|
| Perfusion | 1 | 2013 | 131 | 0.030 |
Why?
|
| Plasmodium berghei | 1 | 2012 | 7 | 0.030 |
Why?
|
| Plasmids | 1 | 2013 | 258 | 0.030 |
Why?
|
| Hypoxia | 1 | 2013 | 169 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2013 | 326 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2012 | 160 | 0.030 |
Why?
|
| Genes, RAG-1 | 1 | 2011 | 4 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2011 | 33 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 901 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2011 | 34 | 0.020 |
Why?
|
| Streptococcus intermedius | 1 | 2011 | 2 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 266 | 0.020 |
Why?
|
| Liposomes | 1 | 2012 | 107 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 2011 | 39 | 0.020 |
Why?
|
| Extracellular Fluid | 1 | 2011 | 29 | 0.020 |
Why?
|
| Clodronic Acid | 1 | 2011 | 9 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 371 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 77 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 15 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 386 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2007 | 1083 | 0.020 |
Why?
|
| Fibrin | 1 | 2010 | 35 | 0.020 |
Why?
|
| Macrophage Activation | 1 | 2011 | 75 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2010 | 65 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 43 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 24 | 0.020 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2010 | 11 | 0.020 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2011 | 46 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 215 | 0.020 |
Why?
|
| Proteinuria | 1 | 2010 | 136 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1196 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 266 | 0.020 |
Why?
|
| Antibodies, Fungal | 1 | 2009 | 9 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2009 | 34 | 0.020 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 27 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 237 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2013 | 902 | 0.020 |
Why?
|
| Asthma | 1 | 2011 | 345 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 175 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2007 | 85 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 136 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2007 | 56 | 0.020 |
Why?
|
| Static Electricity | 1 | 2007 | 91 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2007 | 190 | 0.020 |
Why?
|
| Arginine | 1 | 2007 | 102 | 0.020 |
Why?
|
| Bystander Effect | 1 | 2006 | 10 | 0.020 |
Why?
|
| Fibrosarcoma | 1 | 2006 | 21 | 0.020 |
Why?
|
| Transgenes | 1 | 2006 | 92 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 1026 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 331 | 0.020 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2006 | 44 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1213 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 981 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 1200 | 0.020 |
Why?
|
| Complement C4b | 1 | 2004 | 3 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2004 | 43 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 134 | 0.010 |
Why?
|
| Cell Separation | 1 | 2004 | 132 | 0.010 |
Why?
|
| Glucans | 1 | 2004 | 12 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 63 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2004 | 145 | 0.010 |
Why?
|
| Vaccination | 1 | 2004 | 189 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 1070 | 0.010 |
Why?
|
| Cytochrome P-450 CYP4A | 1 | 1997 | 6 | 0.010 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1997 | 16 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1997 | 90 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 231 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1997 | 251 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 357 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1997 | 282 | 0.010 |
Why?
|
| Base Sequence | 1 | 1997 | 1015 | 0.010 |
Why?
|